Significant nitric oxide (NO) and NO synthase activity has been found in female genital tissue, suggesting a plausible biological explanation for how drugs such as sildenafil, which are used in ...

Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder. Data from a post-hoc analysis of the phase 2b RESPOND ...

Several observations from preclinical and short-term clinical studies support a role for sildenafil in the treatment of heart failure patients. The following discussion briefly considers each of ...

Daré Bioscience, Inc., a company at the forefront of female health and wellness innovation, has recently disclosed its Phase 3 clinical development plans for Sildenafil Cream, 3.6%, intended for ...

Daré Bioscience, in collaboration with Strategic Science & Technologies, announced plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder ...

With Sildenafil Cream’s potential to be the first FDA-approved product for FSAD, Daré is poised to create a new market category within the female sexual dysfunction space. About FSAD and ...

Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.

FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sil ...

"While increased attention has been focused on female sexual dysfunctions over the past several years, no pharmacologic options have yet been FDA approved for FSAD, a condition which significantly ...